@FiercePharma: Elan chief won't fight a new conflicts probe. News | Follow @FiercePharma
> Adcock Ingram, South Africa's largest over-the-counter drugs company, and Baxter Healthcare agreed to arbitration to resolve a dispute over the value of a business that Baxter has the option to buy. Report
> In response to U.S. pricing of Abbott Laboratories' AIDS drug Norvir, an advocacy group plans to petition the National Institutes of Health this month to break several patents on the drug. Report
> Amgen plans to sell $1.5 billion of 10- and 31-year debt as soon as today in its second bond offering this year. Report
> Scottish cost regulators have issued seals of approval for the use of Sanofi-Aventis' heart drug Multaq, Novartis' cancer therapy Glivec, and AstraZeneca's reflux drug Nexium on the National Health Service. Report
> GlaxoSmithKline's clotting disorder drug Revolade has been deemed too expensive for use on the U.K.'s National Health Service by its cost regulator. Report
> Sanofi-Aventis is likely to refinance part of an approximate $10 billion loan in the bond market that the drugmaker has lined up to back its $18.5 billion bid to buy Genzyme. Report
> The asthma drug albuterol can ease the symptoms of multiple sclerosis and delay relapses when added to conventional treatments, but the effects apparently wear off after a year. Report
> Oppenheimer raised its outlook for Teva Pharmaceutical Industries to Outperform, saying that it expects the MS drug Copaxone to maintain market share for the time being. Report
> Roche was downgraded to equal-weight from overweight at Morgan Stanley, which cited a stream of high-profile setbacks for its in-market pipeline drugs. Report
Biotech News
@FierceBiotech: Third Rock gathers $426M for new biotech investments. Article | Follow @FierceBiotech
@JohnCFierce: Seattle Genetics CEO did a good job softening the blow on its trial failure; shares down about 18% anyway. | Follow @JohnCFierce
> Pfizer: Pipeline will redeem underperforming labs. Story
> Ironwood touts positive PhIII IBS results. Item
> Genmab, Seattle Genetics ink cancer research deal. Article
> Italy's Okairos raises $20.5M for vaccine work. Report
Biotech Research News
> AZ, UCL to partner on stem cell cure for diabetic blindness. Article
> NIH funds college research network. News
> Foundation uses gaming to inspire rad R&D thinking. Story
> Berkeley scientists piece together patches of "e-skin." Report
> Amyloid protein fingered for Type 2 diabetes. Article
Manufacturing News
> Axed legal reviews jeopardize regulatory consistency. Story
> Genzyme faces 1,000 job cuts. Article
> Counterfeit Viagra nabbed at Heathrow. Report
> Spare pharma the dot-com cleaver. Item
> Counterfeits questioner needs to dig deeper. Story
> FDA's OK could be start of KV's comeback. News
And Finally ... A pilot study suggests the diabetes medication pioglitazone (Takeda's Actos) may warrant further study as an Alzheimer's treatment, according to a report posted online that will appear in the January 2011 print issue of Archives of Neurology. Report